未知股票 VCNX 深 滬
已收盤
--
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 --
- 最 低 --
- 昨 收 --
- 總市值 0
- 52周最高 --
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 總股本 267.66万
- 歷史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 --
- 每 手 1
- 風險率 2.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Pepinemab, a humanized IgG4 monoclonal antibody targeting SEMA4D, shows potential to transform immunologically cold tumors into hot centers by inducing robust and mature tertiary lymphoid structures (TLS), enhancing immune responses to checkpoint therapies in head and neck cancer patients. Vaccinex, Inc. will present new data at the 2025 ASCO Annual Meeting, highlighting pepinemab's role in improving pathologic responses without increasing toxici...
2025-05-27 12:45
Vaccinex receives delisting notice from Nasdaq, shares down over 49%
Vaccinex (NASDAQ:VCNX) on Tuesday said it has received a Nasdaq notice, indicating that Nasdaq has determined to delist the company’s shares from Nasdaq due to the company’s failure to meet Nasdaq’s c...
2024-12-17 22:17
Vaccinex reports Q3 figures
Vaccinex press release (NASDAQ:VCNX): Q3 GAAP EPS of -$2.83. Revenue of $0.05M (+150.0% Y/Y). More on Vaccinex Financial information for Vaccinex
2024-11-18 22:17
Vaccinex Reports Improved Immunity Correlating With Clinical Benefit Of Pepinemab Combination Treatment At Society For Immunotherapy Of Cancer's Annual Meeting
Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease (NDD) through the inhibition of SEMA4D, today announced that it
2024-11-05 21:32
Capricor Therapeutics, Inc.盘中异动 股价大跌5.02%报20.29美元
北京时间2024年11月01日02时56分，Capricor Therapeutics, Inc.（CAPR.us）股票出现波动，股价快速跳水5.02%。截至发...
2024-11-01 02:56
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Biofrontera (NASDAQ:BFRI) stock increased by 88.0% to $1.76 during Thu...
2024-11-01 00:34
快讯 | Vaccinex将于2024年10月31日在阿尔茨海默病临床研究(Ctad)大会上报告Pepinemab信号AD 1B/2期试验的新疗效数据。
Vaccinex to Report Promising New Efficacy Data for Signal-Ad Phase 1B/2 Trial o...
2024-10-24 20:30
Vaccinex files for secondary stock offering
Vaccinex (NASDAQ:VCNX) files preliminary prospectus for resale by the selling stockholders of up to 1.6M shares of our common stock. SEC Filing More on Vaccinex Vaccinex says Alzheimer's candidate buo...
2024-10-17 05:01
What's Going On With Vaccinex Stock Wednesday?
Vaccinex shares are trading lower on Wednesday after the company announced $6.2 million in proceeds from the exercise of warrants as well as the issuance of new warrants for common stock.
2024-09-19 01:33
Vaccinex exercises warrants for proceeds of $6.2M
Vaccinex (NASDAQ:VCNX) said on Wednesday it has entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 1.07M shares of common stock at the reduced exercise p...
2024-09-18 20:46
